|
GB8529014D0
(en)
|
1985-11-25 |
1986-01-02 |
Biogen Nv |
Enhanced secretion of heterologous proteins
|
|
WO1987005330A1
(en)
|
1986-03-07 |
1987-09-11 |
Michel Louis Eugene Bergh |
Method for enhancing glycoprotein stability
|
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2, Inc., Danville, Calif. |
Geänderte antikörper.
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5096815A
(en)
|
1989-01-06 |
1992-03-17 |
Protein Engineering Corporation |
Generation and selection of novel dna-binding proteins and polypeptides
|
|
US5198346A
(en)
|
1989-01-06 |
1993-03-30 |
Protein Engineering Corp. |
Generation and selection of novel DNA-binding proteins and polypeptides
|
|
US5350836A
(en)
|
1989-10-12 |
1994-09-27 |
Ohio University |
Growth hormone antagonists
|
|
US5959177A
(en)
*
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
|
US6150584A
(en)
*
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6673986B1
(en)
*
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
ATE139258T1
(de)
*
|
1990-01-12 |
1996-06-15 |
Cell Genesys Inc |
Erzeugung xenogener antikörper
|
|
US6075181A
(en)
*
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
WO1992015602A1
(en)
|
1991-02-28 |
1992-09-17 |
Dana-Farber Cancer Institute, Inc. |
Cancer diagnosis and therapy
|
|
FI941572A7
(fi)
*
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
|
|
US5288931A
(en)
|
1991-12-06 |
1994-02-22 |
Genentech, Inc. |
Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
|
|
US5660827A
(en)
*
|
1992-03-05 |
1997-08-26 |
Board Of Regents, The University Of Texas System |
Antibodies that bind to endoglin
|
|
US5965132A
(en)
*
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
|
US5830847A
(en)
*
|
1992-10-30 |
1998-11-03 |
Hsc Research & Development Limited Partnership |
Soluble TGF-β-binding endoglin polypeptides and homodimers
|
|
CA2147754A1
(en)
|
1992-10-30 |
1994-05-11 |
Michelle Letarte |
Compositions and methods for modifying the regulatory activity of tgf- .beta.
|
|
US6692925B1
(en)
*
|
1992-11-17 |
2004-02-17 |
Ludwig Institute For Cancer Research |
Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
|
|
DE69332779T2
(de)
|
1992-11-17 |
2003-10-23 |
Ludwig Institut For Cancer Research, Padington |
Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen
|
|
US7592428B1
(en)
|
1992-11-17 |
2009-09-22 |
Ludwig Institute For Cancer Research |
Antibodies which bind specifically to activin receptor like kinases
|
|
EP0690871A4
(en)
*
|
1993-01-12 |
1999-10-20 |
Univ Johns Hopkins Med |
GROWTH DIFFERENTIATION FACTOR-5
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
|
US5541087A
(en)
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
|
US5925351A
(en)
|
1995-07-21 |
1999-07-20 |
Biogen, Inc. |
Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
|
|
AU709991B2
(en)
|
1995-08-14 |
1999-09-09 |
Creative Biomolecules, Inc. |
Binding of osteogenic protein-1 (OP-1) and analogs thereof to the cell surface receptor ALK-1 and analogs thereof
|
|
US6190660B1
(en)
*
|
1996-05-31 |
2001-02-20 |
Health Research, Inc. |
Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
|
|
EP0938505B1
(en)
*
|
1996-05-31 |
2002-03-06 |
Health Research, Inc. |
Anti-endoglin monoclonal antibodies and their use in anti-angiogenesis therapy
|
|
MX9701946A
(es)
|
1997-03-14 |
1998-04-30 |
Arturo Jimenez Bayardo |
Solucion oftalmica transportadora.
|
|
AU7467898A
(en)
|
1997-04-21 |
1998-11-13 |
Arch Development Corporation |
Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy
|
|
JP2001510042A
(ja)
|
1997-07-15 |
2001-07-31 |
イミュネックス・コーポレーション |
Ｔｒａｉｌ受容体
|
|
AU3092899A
(en)
|
1998-03-13 |
1999-09-27 |
Ludwig Institute For Cancer Research |
Alk-1 responds to tgf-beta and signals through smad-1 and smad-5
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
PT1068241E
(pt)
|
1998-04-02 |
2007-11-19 |
Genentech Inc |
Variantes de anticorpos e respectivos fragmentos
|
|
US20030012792A1
(en)
*
|
1998-05-22 |
2003-01-16 |
Holaday John W. |
Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
|
|
US6413513B1
(en)
*
|
1998-05-22 |
2002-07-02 |
Entremed, Inc. |
Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
|
|
GB9912350D0
(en)
|
1999-05-26 |
1999-07-28 |
European Molecular Biology Lab Embl |
Modified cytokine
|
|
EP1187843A1
(en)
*
|
1999-06-03 |
2002-03-20 |
Human Genome Sciences, Inc. |
Angiogenic proteins and uses thereof
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
US7740841B1
(en)
|
2000-01-28 |
2010-06-22 |
Sunnybrook Health Science Center |
Therapeutic method for reducing angiogenesis
|
|
ATE369359T1
(de)
|
2000-02-15 |
2007-08-15 |
Sugen Inc |
Pyrrol substituierte indolin-2-on protein kinase inhibitoren
|
|
US7077836B2
(en)
*
|
2000-07-21 |
2006-07-18 |
Vein Rx, Inc. |
Methods and apparatus for sclerosing the wall of a varicose vein
|
|
CA2417982A1
(en)
|
2000-08-03 |
2002-02-14 |
The University Of Utah Research Foundation |
Manipulation of arterial-venous identity
|
|
DE10043481A1
(de)
|
2000-09-04 |
2002-04-11 |
Vectron Therapeutics Ag Imt |
Humaner Antikörper gegen Endoglin (CD105) und seine Verwendung
|
|
ATE430742T1
(de)
|
2000-12-21 |
2009-05-15 |
Smithkline Beecham Corp |
Pyrimidinamine als angiogenesemodulatoren
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
FI117667B
(fi)
|
2001-07-05 |
2007-01-15 |
Univ Zuerich |
Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
|
|
MXPA04003697A
(es)
|
2001-10-31 |
2005-04-08 |
Alcon Inc |
Proteinas morfogenicas de hueso (bmp), receptores de bmp y proteinas de enlace de bmp y su uso en el diagnostico y tratamiento de glaucoma.
|
|
WO2003064628A2
(en)
|
2002-02-01 |
2003-08-07 |
Curagen Corporation |
Novel proteins and nucleic acids encoding same
|
|
KR100956195B1
(ko)
|
2002-02-01 |
2010-05-06 |
어리어드 파마슈티칼스, 인코포레이티드 |
인 함유 화합물 및 이의 용도
|
|
US7045534B2
(en)
*
|
2002-02-12 |
2006-05-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of reducing angiogenesis
|
|
WO2003093293A2
(en)
|
2002-04-29 |
2003-11-13 |
Saint Louis University |
Peptide antagonists of tgf-beta family members and therapeutic uses thereof
|
|
EP1534318A4
(en)
|
2002-06-27 |
2009-07-01 |
Univ Utah Res Found |
METHOD AND COMPOSITIONS FOR MANIPULATING GUIDED NAVIGATION OF ENDOTHONE TUBES IN THE ANGIOGENESIS
|
|
US20060140914A1
(en)
|
2002-10-31 |
2006-06-29 |
The General Hospital Corporation |
Repairing or replacing tissues or organs
|
|
WO2005010049A2
(en)
|
2003-07-09 |
2005-02-03 |
Eli Lilly And Company |
Tgf-beta1 ligands
|
|
WO2005044849A2
(en)
|
2003-08-05 |
2005-05-19 |
Eli Lilly And Company |
Lp mammalian proteins; related reagents
|
|
WO2005077981A2
(en)
*
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
|
EP1721257A2
(en)
|
2004-01-27 |
2006-11-15 |
Compugen Ltd. |
Differential expression of markers in ovarian cancer
|
|
US7575751B2
(en)
|
2004-04-27 |
2009-08-18 |
Research Development Foundation |
Activin-A mutants
|
|
US7741284B2
(en)
|
2004-05-12 |
2010-06-22 |
Acceleron Pharma Inc. |
BMP10 propeptides and related methods
|
|
ES2426005T3
(es)
*
|
2004-07-23 |
2013-10-18 |
Acceleron Pharma Inc. |
Polipéptidos del receptor ACTRII, procedimientos y composiciones
|
|
WO2006091930A2
(en)
*
|
2005-02-24 |
2006-08-31 |
Massachusetts Eye & Ear Infirmary |
Methods and compounds for promoting vessel regression
|
|
AU2006223301B2
(en)
*
|
2005-03-10 |
2010-11-04 |
Eisai, Inc. |
Anti-mesothelin antibodies
|
|
CN101517068B
(zh)
|
2005-09-07 |
2017-02-08 |
安进弗里蒙特公司 |
活化素受体样激酶‑1的人单克隆抗体
|
|
JP2009534035A
(ja)
|
2006-04-21 |
2009-09-24 |
ワイス |
細胞系のハイスループットスクリーニング方法
|
|
US20090170767A1
(en)
|
2006-05-31 |
2009-07-02 |
Beth Israel Deaconess Medical Center |
Soluble Endoglin Compounds for the Treatment and Prevention of Cancer
|
|
MX2009004718A
(es)
|
2006-11-02 |
2009-06-19 |
Acceleron Pharma Inc |
Antagonistas de receptor de alk1 y ligando y sus usos.
|
|
US10059756B2
(en)
|
2006-11-02 |
2018-08-28 |
Acceleron Pharma Inc. |
Compositions comprising ALK1-ECD protein
|
|
US8642031B2
(en)
*
|
2006-11-02 |
2014-02-04 |
Acceleron Pharma, Inc. |
Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
|
|
PE20090983A1
(es)
*
|
2007-11-09 |
2009-08-13 |
Genentech Inc |
Composiciones y metodos de uso de la quinasa-1 similar al receptor de la activina
|
|
KR20110031908A
(ko)
*
|
2008-05-02 |
2011-03-29 |
악셀레론 파마 인코포레이티드 |
혈관신생 및 혈관주위세포 적용범위의 조정을 위한 ａｌｋ１ 길항제 기재의 방법 및 조성물
|
|
CA2724525A1
(en)
|
2008-05-15 |
2009-11-19 |
Acceleron Pharma, Inc. |
Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
|
|
US8715926B2
(en)
|
2008-11-24 |
2014-05-06 |
Loma Linda University |
Biomarkers for the detection of head and neck tumors
|
|
EP2427494B1
(en)
|
2009-05-08 |
2017-10-18 |
Novartis AG |
Methods of modulating fibrosis using bone morphogenetic protein-9 (bmp-9) modulators
|
|
AU2012212047A1
(en)
|
2011-02-03 |
2013-08-22 |
Xoma Technology Ltd. |
Methods and materials for enhancing functional protein expression in bacteria
|
|
CA2863188A1
(en)
|
2012-02-02 |
2013-08-08 |
Acceleron Pharma Inc. |
Alk1 antagonists and their uses in treating renal cell carcinoma
|
|
US20140193425A1
(en)
|
2012-10-05 |
2014-07-10 |
Acceleron Pharma, Inc. |
Treatment of cancer with alk1 antagonists
|
|
CA2944335A1
(en)
|
2014-03-28 |
2015-10-01 |
Acceleron Pharma, Inc. |
Use of activin receptor-like kinase 1 (alk-1) antagonists in the treatment of cancer
|